RPP25

Across TCGA pan-cancer cohorts, RPP25 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RPP25 data layer compared with 27 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher RPP25 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated RPP25 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

GBM, CCRCC, and PDAC are the cancer types where RPP25 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Tertile	All	0.220	0.699	<.001	14	view →
CCRCC	DFS	Quartile	All	0.491	1.000	.012	12	view →
PDAC	DFS	Quartile	III,IV	0.607	0.943	.022	7	view →
LUAD	DFS	Quartile	II,III,IV	0.261	0.624	.010	5	view →
LSCC	DFS	Median	All	0.991	0.560	.016	3	view →
HNSC	DFS	Quartile	III,IV	0.442	0.746	.039	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RPP25–GBM (OS)

Open the GBM breakdown →